Neuromeka's Conversion Price Upward Adjustment Reduces Dilution Risk Amid Stock Price Rise

Neuromeka adjusted the conversion price of its first series convertible bond upward from 30,867 KRW to 35,289 KRW.
The adjustment reflects the recent stock price increase, reducing the number of convertible shares from 65,442 to 57,241, a decrease of 8,201 shares.
The higher conversion price lowers potential dilution, protecting existing shareholder value.
[AI Summary]Neuromeka's upward conversion price adjustment reflects rising stock prices, reducing potential dilution and benefiting existing shareholders. The impact on capital structure is minor but signals market confidence.